Kaitlyn D’Onofrio

DocwireNews

A study recently published in <a href="https://ard.bmj.com/content/early/2019/09/27/annrheumdis-2019-215386">Annals of the Rheumatic Diseases</a> found that <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/ixekizumab-adalimumab-active-psa/">ixekizumab</a> may be superior to <a href="https://www.docwirenews.com/docwire-pick/adalimumab-safe-for-children/">adalimumab</a> in biologic-na&iuml;ve <a href="https://www.docwirenews.com/abstracts/rheumatology-abstracts/secukinumab-as-biological-treatment-for-psoriatic-arthritis-in-real-clinical-practice/">psoriatic arthritis</a> (PsA) patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).&ldquo;Some evidence suggests that combination therapy with csDMARDs such as methotrexate may inhibit development of antidrug antibodies to [biologic] DMARDs, and some studies observed better treatment persistence with combination therapy. Concomitant methotrexate has been associated with greater serum concentration of adalimumab (ADA) versus patients receiving ADA monotherapy,&rdquo; the researchers wrote. Therefore, the study authors compared ixekizumab, &ldquo;a high-affinity monoclonal antibody that selectively targets IL-17A,&rdquo; to tumor necrosis factor &alpha; inhibitor adalimumab.The trial was an open-label, head-to-head, blinded assessor clinical trial. Patients with active PsA were randomized 1:1 to receive <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/taltz-vs-cosentyx-how-do-these-rheumatic-drugs-compare/">ixekizumab</a> or <a href="https://www.docwirenews.com/docwire-pick/fda-approves-biosimilar-adalimumab/">adalimumab</a>. The primary outcome was 24-week simultaneous achievement of a &ge; 50% improvement from baseline in the American College of Rheumatology criteria (ACR50) and a 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI100). Secondary outcomes included 24-week outcomes regarding ixekizumab non-inferiority to adalimumab for ACR50 achievement and ixekizumab superiority to PASI10 responses. Other 24-week PsA, skin, treat-to-target, and quality of life outcome measures were also assessed.&ldquo;The primary efficacy endpoint was met (IXE: 36%, ADA: 28%; p=0.036),&rdquo; the study authors reported. ACR50 response was slightly better in the ixekizumab group than adalimumab (51% vs. 47%; treatment difference, 3.9%); the improvement in PASI100 response was more significant (60% vs. 47%, respectively; P = 0.001). Additional analyses of PsA, skin, nail, treat-to-target, and quality of life outcomes were also in favor of ixekizumab. The adalimumab group had a higher rate of serious adverse events than the ixekizumab cohort (8.5% vs. 3.5%).&ldquo;Treatment choices for PsA in clinical practice are made between medications that have shown efficacy and sufficient safety in clinical trials. Because comparative clinical trials are rare in PsA, indirect comparisons are often made using meta-analyses. However, head-to-head trials where active agents are compared, rather than an active agent and placebo, offer the highest level of evidence,&rdquo; the authors wrote of their research.The researchers concluded that ixekizumab was superior in comparison to adalimumab over a 24-week period.

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

Ixekizumab vs. Adalimumab for PsA: A Drug Comparison

Psoriatic Arthritis

A study recently published in Annals of the Rheumatic Diseases found that ixekizumab may be superior to adalimumab in biologic-naïve psoriatic arthritis (PsA) patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe